CINRYZE

BIOLOGICAL3 trials

Sponsors

Shire, University of Wisconsin, Madison

Conditions

Hereditary AngioedemaHereditary Angioedema (HAE)Kidney Failure

Phase 1

CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%

University of Wisconsin, MadisonKidney Failure

Start: 2020-12-31End: 2022-05-31Target: 72Updated: 2020-10-22

Phase 2

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

CompletedNCT01095510

ShireHereditary Angioedema (HAE)

Start: 2010-06-02End: 2012-04-17Updated: 2021-06-03

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration

CompletedNCT01095497

ShireHereditary Angioedema

Start: 2010-06-07End: 2010-12-16Updated: 2021-07-09